Last reviewed · How we verify
Azacitidine associated with Idarubicine
Azacitidine is a DNA methyltransferase inhibitor, and Idarubicin is an anthracycline antibiotic that intercalates DNA.
Azacitidine is a DNA methyltransferase inhibitor, and Idarubicin is an anthracycline antibiotic that intercalates DNA. Used for Acute myeloid leukemia.
At a glance
| Generic name | Azacitidine associated with Idarubicine |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | DNA methyltransferase inhibitor, Anthracycline antibiotic |
| Target | DNA methyltransferase, DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Azacitidine works by inhibiting DNA methyltransferase enzymes, leading to hypomethylation of DNA and changes in gene expression. Idarubicin intercalates DNA strands, thereby inhibiting the synthesis of macromolecules and inducing apoptosis in cancer cells.
Approved indications
- Acute myeloid leukemia
Common side effects
- Myelosuppression
- Nausea and vomiting
- Fatigue
Key clinical trials
- Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (PHASE2)
- Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic Syndromes (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: